Session » Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III
- 9:00AM-11:00AM
-
Abstract Number: 1370
A Delayed Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
- 9:00AM-11:00AM
-
Abstract Number: 1353
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
- 9:00AM-11:00AM
-
Abstract Number: 1362
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
- 9:00AM-11:00AM
-
Abstract Number: 1364
Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
- 9:00AM-11:00AM
-
Abstract Number: 1352
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
- 9:00AM-11:00AM
-
Abstract Number: 1358
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
- 9:00AM-11:00AM
-
Abstract Number: 1355
Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials
- 9:00AM-11:00AM
-
Abstract Number: 1357
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
- 9:00AM-11:00AM
-
Abstract Number: 1343
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
- 9:00AM-11:00AM
-
Abstract Number: 1372
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement
- 9:00AM-11:00AM
-
Abstract Number: 1351
Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study
- 9:00AM-11:00AM
-
Abstract Number: 1363
Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
- 9:00AM-11:00AM
-
Abstract Number: 1369
Efficacy of Tildrakizumab in PsA: DAPSA Remission and Low Disease Activity in PASDAS Through Week 52
- 9:00AM-11:00AM
-
Abstract Number: 1356
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs
- 9:00AM-11:00AM
-
Abstract Number: 1342
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
- 9:00AM-11:00AM
-
Abstract Number: 1349
Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 1344
Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
- 9:00AM-11:00AM
-
Abstract Number: 1373
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
- 9:00AM-11:00AM
-
Abstract Number: 1376
Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis
- 9:00AM-11:00AM
-
Abstract Number: 1367
Impact of Ixekizumab on Work Productivity in Non-Radiographic Axial Spondyloarthritis Patients: Results from the COAST-X Trial at 52 Weeks
- 9:00AM-11:00AM
-
Abstract Number: 1371
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs
- 9:00AM-11:00AM
-
Abstract Number: 1341
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
- 9:00AM-11:00AM
-
Abstract Number: 1365
Machine Learning-based Berlin Scoring of Magnetic Resonance Images of the Spine in Patients with Ankylosing Spondylitis: Analysis of Data from a Phase 3 Trial with Secukinumab
- 9:00AM-11:00AM
-
Abstract Number: 1360
New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study
- 9:00AM-11:00AM
-
Abstract Number: 1346
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
- 9:00AM-11:00AM
-
Abstract Number: 1347
Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study
- 9:00AM-11:00AM
-
Abstract Number: 1368
Proportions of Patients Achieving a Minimal Disease Activity State upon Treatment with Tildrakizumab in a Psoriatic Arthritis Phase 2b Study
- 9:00AM-11:00AM
-
Abstract Number: 1375
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?
- 9:00AM-11:00AM
-
Abstract Number: 1350
Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis from Two Phase 3 Trials
- 9:00AM-11:00AM
-
Abstract Number: 1366
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation
- 9:00AM-11:00AM
-
Abstract Number: 1340
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
- 9:00AM-11:00AM
-
Abstract Number: 1374
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
- 9:00AM-11:00AM
-
Abstract Number: 1361
Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naïve Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study
- 9:00AM-11:00AM
-
Abstract Number: 1359
Targeted Serum Proteomic Analysis Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue Repair Modulation
- 9:00AM-11:00AM
-
Abstract Number: 1354
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis